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Background: Recently, we clarified at the molecular level novel chromosomal translocation t(14;14)(q11;q32) in a
case of Sézary syndrome, which caused a rearrangement from TRAJ7 to the PPP2R5C gene. PPP2R5C is one of the
regulatory B subunits of protein phosphatase 2A (PP2A). It plays a crucial role in cell proliferation, differentiation,
and transformation. To characterize the expression and distribution of five different transcript variants of the
PPP2R5C gene in leukemia, we analyzed the expression level of PPP2R5C in peripheral blood mononuclear cells
from 77 patients with de novo leukemia, 26 patients with leukemia in complete remission (CR), and 20 healthy
individuals by real-time PCR and identified the different variants of PPP2R5C by RT-PCR.
Findings: Significantly higher expression of PPP2R5C was found in AML, CML, T-ALL, and B-CLL groups in
comparison with healthy controls. High expression of PPP2R5C was detected in the B-ALL group; however, no
significant difference was found compared with the healthy group. The expression level of PPP2R5C in the CML-CR
group decreased significantly compared with that in the de novo CML group and was not significantly different
from the level in the healthy group. By using different primer pairs that covered different exons, five transcript
variants of PPP2R5C could be identified. All variants could be detected in healthy samples as well as in all the
leukemia samples, and similar frequencies and distributions of PPP2R5C were indicated.
Conclusions: Overexpression of PPP2R5C in T-cell malignancy as well as in myeloid leukemia cells might relate to
its proliferation and differentiation. Investigation of the effect of target inhibition of this gene might be beneficial
to further characterization of molecular mechanisms and targeted therapy in leukemia.
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Background
Molecular genetic aberrations could provide the basis
for assays that can predict prognosis of individual
patients as well as potential molecular targets for novel
therapies [1-3]. The process of malignant transformation
in leukemia is complex, and many factors such as
abnormal gene expression and mutation, chromosomal
aberrations, deregulation of various cellular signaling
pathways, and deregulation of epigenetic regulation are
involved in the development of leukemia [1]. Therefore,
new data regarding molecular genetic aberrations in
different types of leukemia are needed for further
characterization.
PPP2R5C is one of the regulatory B subunits of
protein phosphatase 2A (PP2A), which is a major cellu-
lar serine/threonine phosphatase that affects the phos-
phorylation status of many proteins [4]. The PPP2R5C
gene encodes five differentially spliced variants: B56g1,
B56g2, B56g3, B56g5, and B56g6 (Figure 1), whereas
B56g4 is identified only in mice. The functional
PPP2R5C gene locus resides at 14q32.2, whereas a non-
functional B56g1p s e u d o g e n ePPP2R5C is present at
3p21.3 [4,5]. PPP2R5C plays a crucial role in cell prolif-
eration, differentiation, and transformation, based on its
induction of dephosphorylation of P53 at various resi-
dues [6]. It has been reported that the dynamic nuclear
distribution of the B56g3 regulatory subunit controls
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tumor-suppression function of PP2A [5]. Recently, the
alteration of the expression pattern of PPP2R5C asso-
ciated with malignant transformation has been charac-
terized in lung cancer; a PPP2R5C mutation, F395C,
disrupts B56g-p53 interaction [7].
Based on our recent finding of a novel chromosomal
translocation t(14;14)(q11;q32) that was involved in a
gene rearrangement from TRAJ7 to PPP2R5C in a
patient with Sézary syndrome (data unpublished), in the
present study, we further characterized the expression
and distribution of five different transcript variants of
the PPP2R5C gene in leukemia.
Methods
Samples
Seventy-seven newly diagnosed and untreated cases of
leukemia, including 24 with acute myeloid leukemia
(AML); 14 with chronic phase chronic myeloid leukemia
(CML); 18 with T-cell acute lymphocytic leukemia/lym-
phoma (T-ALL); 12 with B-cell ALL (B-ALL); and nine
with B-cell chronic lymphocytic leukemia (B-CLL).
Twenty-six cases with leukemia in complete remission
(CR) (nine with AML-CR, three with B-ALL-CR and 14
with CML-CR) were selected, along with 20 healthy
individuals as controls. The samples were collected with
informed consent. All procedures were conducted in
Figure 1 Genomic organization of PPP2R5C. The bars represent the exons, and the lines represent introns. The pink bars are the 5’ UTR, the
black bars are exons that were identical in all five variants (exons 2-12), the colored bars represent specific exons in different variants, the 3’ UTR
in different variants is shown with green bars (variants 1, 2, 5 and 6), horizontal-dash-filled pink bars (variant 3), and horizontal-line-filled bars
(pseudogene). The coding sequence between exons 2 and 12 and the shown splice junction (downward arrow) were identical across the five
splice variants. The location and direction of primers used for amplification of different variants are indicated by arrows [4].
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committees of the Health Bureau of Guangdong Pro-
vince, China. Human leukemia cell lines Hut-78, CCRF,
Jurkat, Molt-3, Molt-4, K562, NB4, Raji and Daudi were
used in the study. The RNA extraction and cDNA
synthesis were performed according to the manufac-
turer’s instructions.
Real-time quantitative RT-PCR (qRT-PCR)
Expression levels of PPP2R5C and the reference gene
b2-MG were determined by SYBR Green I real-time
PCR. PCR was performed as our previous description
[8]. The 2
(-ΔΔCT) method was used to present the data
of the genes of interest relative to an internal control
gene [8,9]. The sequences of primers used in qRT-PCR
were PPP2R5C-for: 5’-GTAATAAAGCGGGCAG-
CAGG-3’ and PPP2R5C-bac: 5’-CAAAGT CAAAGAG-
GACGCAACA-3’ for PPP2R5C gene amplification,
b2M-for: 5’-CAGCAAGG ACTGGTCTTTCTAT-3’ and
b2M-bac: 5’-GCGGCATCTTCAAACCTC-3’ for b2M
gene amplification.
Primer design and RT-PCR
To amplify five transcript variants of PPP2R5C accord-
ing the structure of the PPP2R5C gene (accession
nos. NM_002719.3, NM_178586.2, NM_178587.2,
NM_001161725.1 and NM_001161726.1) (Figure 1) [4],
we designed 4-pair primers, which covered different
exons (Table 1) and confirmed the transcript 3, 5, or 6;
however, we were unable to distinguish between tran-
scripts 1 and 5 or transcripts 2 and 6 (Table 2) when
positive products were shown in the sample. RT-PCR
was performed as in our previous study [10].
Results and Discussion
Expression level of PPP2R5C in leukemia
PPP2R5C as a potential tumor suppressor plays a crucial
role in cell proliferation and differentiation [4]. Based on
our recent finding of a novel gene rearrangement from
TRAJ7 to PPP2R5C, it could be interesting to analyze
the expression features of PPP2R5C in hematological
malignancies. In the present study, we analyzed the
expression level of the PPP2R5C gene in leukemia sam-
ples. In comparison with healthy controls (1.24 ± 1.09),
significantly higher expression of PPP2R5C was found in
the AML (2.06 ± 0.85) (p = 0.0076), CML (6.78 ± 2.75)
(p < 0.0001), T-ALL/NHL (3.73 ± 3.66) (p = 0.0062)
and B-CLL (2.21 ± 1.22) (p = 0.0417) groups (Figure 2).
A high tendency toward expression of PPP2R5C was
detected in the B-ALL group (1.39 ± 1.31); however, the
expression was not significantly different from that in
the controls (p = 0.7089) (Figure 2). The expression
level of PPP2R5C in the CML-CR group (1.75 ± 0.55)
decreased significantly in comparison with the CML
group (p < 0.0001), but showed no significant difference
compared with the healthy group (p = 0.2895). Although
the expression level of PPP2R5C gene decreased in the
AML-CR (1.53 ± 0.60) and B-ALL groups (0.54 ± 0.27),
there was no significant difference compared with the
AML (p = 0.1100) and B-ALL groups (p = 0.2142) or
with healthy controls. Overexpression of PPP2R5C was
found in T-cell lines like Hut-78, CCRF, Jurkat, Molt-3
and Molt-4, and the expression level was 5-9 times
higher than that from healthy CD3
+ T cells (Figure 3A).
Interesting, the tendency of the expression level of
PPP2R5C in Raji, Daudi, NB4 and K562 cells was accor-
dant to the results from prima r yl e u k e m i ac e l l s( F i g u r e
3B), which showed higher expression level of PPP2R5C
in K562 (CML cell line), and lower expression level in
B-cell lines (Raji and Daudi).
Mutation, deletion, or abnormal expression of tumor-
suppressor genes is frequently identified in leukemia
[1,11,12]. To the best of our knowledge, no study
h a sb e e nr e p o r t e dt h a te x a m i n e dt h ee x p r e s s i o no f
PPP2R5C in leukemia, except for B-CLL. The present
results identifying PPP2R5C overexpression in most
cases of leukemia might have a similar significance in
cell transformation. Definitive results for the associa-
tion of the expression level of PPP2R5C with disease
progression and outcome could be demonstrated by a
Table 1 Information on primers used in RT-PCR for PPP2R5C segments amplification
primer sequence Location function
PPP2R5C-1f 5’-TGAAAGAACGGGAAGAAGCAT - 3’ 1407 bp (12 exon) Sense primer
PPP2R5C-1b 5’-TGATTGGTATGGCACAGGAAG - 3’ 1801 bp (14 exon) Antisense primer
PPP2R5C-3f 5’-CAGTGACAACGCAGCGAAGAT - 3’ 1216 bp (10 exon) Sense primer
PPP2R5C-3b 5’-ATAAAAACATTCAAGTAACCCTGG-3’ 1520 bp (12a exon) Antisense primer
PPP2R5C-5f 5’-TCCACTTCTTCCTGAGTTGCTG-3’ 230 bp (III exon) Sense primer
PPP2R5C-5b 5’-CTTCTGGGTAAATAGGCTCTGT-3’ 472 bp (2 exon) Antisense primer
PPP2R5C-6f 5’-AGCCTTGTTGCTGTCCCGTCT - 3’ 210 bp (IV exon) Sense primer
PPP2R5C-6b 5’-GTCAAAGAGGACGCAACACTG - 3’ 423 bp (2 exon) Antisense primer
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complete remission. In contrast, Fält et al.h a v e
described that downregulated PPP2R5C is related to
progressive B-CLL by using the Affymetrix GeneChip
technique, and they have concluded that PPP2R5C
could be a marker of progres s i v ed i s e a s ei nB - C L L .
They have compared expression of PPP2R5C between
stable and progressive B-CLL, but not with a healthy
control group [13]. In the present study, we found that
expression of PPP2R5C was significantly increased in
t h eB - C L Lg r o u p ,s i m i l a rt oA M L ,C M L ,a n dT - A L L ;
however, we were unable to collect samples from
patients in complete remission and from those with
progressive disease to compare the expression level and
evaluate the significance of PPP2R5C d e t e c t i o ni nB -
CLL. Further investigation is needed. Unlike most
leukemia cases, the expression level of PPP2R5C in the
B-ALL group, as well as in B-cell lines did not differ
significantly from that in the controls, but it remains
unknown whether this was due to the limited number
of samples or whether it reflects a true feature of
PPP2R5C in B-ALL.
Distribution of PPP2R5C transcript variants in healthy
individuals and leukemia
I th a sb e e nr e p o r t e dt h a tf i v et r a n s c r i p tv a r i a n t so f
PPP2R5C might contribute to the specificity of PP2A
[4]. However, little is known about the distribution of
different variants in different organs, tissues, and cells,
as well as in leukemia cells. Based on the structure of
the PPP2R5C gene reported from Genbank and previous
studies [4], we drew a schematic diagram of the geno-
mic organization of PPP2R5C with five transcript var-
iants (Figure 1), designed four primer pairs to amplify
different exons, and tried to identify different variants in
the same sample. By using PPP2R5C-1f/PPP2R5C-1b,
which covered exons 12-14, two expected PCR products
were detected. The small one comprised 277 bp con-
taining exon 12 and 14 segments (corresponding to
B56g2o rB 5 6 g6), and the large one comprised 394 bp
containing exon 12, 13, and 14 segments (correspond-
ing to B56g3o rB 5 6 g5). PPP2R5C-3f/PPP2R5C-3b,
PPP2R5C-5f/PPP2R5C-5b, and PPP2R5C-6f/PPP2R5C-
6b primer pairs covered exons 10 to 12a, exon III to 2,
and exon IV to 2, respectively, and the expected PCR
products were 304, 242, and 213 bp (corresponding
to transcript B56g1, B56g5, and B56g6 respectively)
(Table 2 Figure 4). According the structure of transcript
variants of PPP2R5C gene and the size of the amplicons,
we confirmed the B56g1, B56g5, and B56g6v a r i a n t s .
However, using the designed primer pairs, we were
unable to distinguish between transcripts 1 and 5 or
between transcripts 2 and 6 because PCR products of
t h es a m es i z ew e r ea m p l i f i e db yu s i n gt h eP P P 2 R 5 C - 1 f /
Table 2 Amplified PCR products using different primer pairs











12 + 13 + 14 exons
(394 bp)
+
12 + 14 exons (277 bp)
-+
12 + 13 + 14 exons
(394 bp)
+
12 + 14 exons (277 bp)
PPP2R5C3f/PPP2R5C3b - - +
10 + 11 + 12 + 12a exons
(304 bp)
--
PPP2R5C5f/PPP2R5C5b - - - +
III + 2 exons
(242 bp)
-
PPP2R5C6f/PPP2R5C6b - - - - +
IV + 2 exons
(213 bp)
Figure 2 Expression level of PPP2R5C in human leukemic cell
line. A: T-cell lines and healthy CD3
+ T cells, B: Myeloid cell lines
and B cell lines and PBMCs from healthy individuals.
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using different primer pair combinations, except for
whole gene sequencing. B56g3( v a r i a n t1 )a n dB 5 6 g2
(variant 2) are the frequency variants; therefore, it is
thought that they might be expressed when positive
PCR products are found. More importantly, using the
present methods, we confirmed the expression of B56g5
and B56g6, which have been newly identified. Therefore,
it could be concluded that all variants can be detected
in healthy as well as leukemia samples with a similar
frequency and distribution of PPP2R5C.
In conclusion, to the best of our knowledge, this is the
first description of the expression level of the PPP2R5C
gene as well as the distribution of PPP2R5C transcript
variants in PBMCs from different types of leukemia.
Overexpression of PPP2R5C i sac o m m o nf e a t u r ei n
most types of leukemia; thus, the change in expression
pattern might influence the activity of PP2A and could
be related to abnormal cell proliferation, differentiat-
ion, and transformation. Further research on the
downregulation of PPP2R5C in leukemia cells is needed
to investigate its biological function.
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